methyl 3-oxo-5-(phenylthio)pentanoate | 51849-20-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: methyl 3-oxo-5-(phenylthio)pentanoate
• 英文别名: methyl 3-oxo-5-phenylthiopentanoate；methyl 5-phenylthio-3-oxopentanoate；methyl 5-phenylthio-3-oxo-pentanoate；3-Oxo-5-phenylthiopentansaeuremethylester；methyl 3-oxo-5-phenylsulfanylpentanoate
• CAS: 51849-20-8
• 化学式: C₁₂H₁₄O₃S
• 分子量: 238.307
• InChiKey: LQQVPQYWELNQJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  68.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-oxo-5-(phenylthio)pentanoate 在 calcium hydroxide 、 间氯过氧苯甲酸 作用下， 以 氯仿 、 异丙醇 为溶剂， 反应 2.5h， 生成 methyl 3-<2-(phenylsulfonyl)ethyl>quinoxaline-2-carboxylate 1,4-dioxide
  参考文献：
  名称：

  Pyridoquinoxaline N-oxides. 1. A new class of antitrichomonal agents

  摘要：

  DOI：

  10.1021/jm00349a021
• 作为产物：
  描述：

  氯甲基苯硫醚 在 sodium iodide 作用下， 以 丙酮 为溶剂， 生成 methyl 3-oxo-5-(phenylthio)pentanoate
  参考文献：
  名称：

  New synthetic reactions. Convenient approach to methyl 3-oxo-4-pentenoate

  摘要：

  DOI：

  10.1021/jo00931a052

文献信息

• 1,4-dihydropyridine compounds as bradykinin antagonists
  申请人：Pfizer Inc.

  公开号：US06131226A1

  公开（公告）日：2000-10-17

  A compound of formula (I) and its pharmaceutically acceptable salts, wherein A.sup.1 and A.sup.2 are each halo; X is direct bond, CH.sub.2, CO, O, S, S(O) or S(O).sub.2 ; R.sup.1 is selected from a variety of groups such as hydrogen; substituted or unsubstituted C.sub.1-4 alkyl; substituted or unsubstituted piperidinyl; substituted or unsubstituted C.sub.5-14 cycloalkyl, bicycloalkyl or tricycloalkyl; substituted or unsubstituted C.sub.7-14 azacyclo-, azabicyclo- or azatricyclo-alkyl; bicyclo C.sub.7-10 alkenyl; benzocyclo C.sub.5-7 alkyl; and heterocyclic; R.sup.2 is hydrogen, C.sub.1-4 alkyl, substituted or unsubstituted phenyl or heterocyclic; and R.sup.3 and R.sup.4 are each C.sub.1-5 alkyl. The novel dihydropyridine compounds of this invention have excellent bradykinin antagonistic activity and are thus useful for the treatment of inflammation, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma or the like in mammalian, especially humans. ##STR1##

  该公式(I)的化合物及其药学上可接受的盐，其中A.sup.1和A.sup.2分别为卤素；X为直链键，CH.sub.2，CO，O，S，S(O)或S(O).sub.2；R.sup.1选自各种基团，如氢；取代或未取代的C.sub.1-4烷基；取代或未取代的哌啶基；取代或未取代的C.sub.5-14环烷基，双环烷基或三环烷基；取代或未取代的C.sub.7-14氮杂环烷基，氮杂双环烷基或氮杂三环烷基；双环C.sub.7-10烯基；苯并环C.sub.5-7烷基；和杂环基；R.sup.2为氢，C.sub.1-4烷基，取代或未取代的苯基或杂环基；R.sup.3和R.sup.4分别为C.sub.1-5烷基。本发明的新型二氢吡啶化合物具有优异的激肽酶抑制活性，因此可用于治疗哺乳动物，尤其是人类的炎症、心血管疾病、疼痛、感冒、过敏、哮喘、胰腺炎、烧伤、病毒感染、头部损伤、多发伤等。
• The Carbon Zip Reaction: A Method for Expanding Carbocycles
  作者：Yoshihiko Nakashita、Manfred Hesse

  DOI：10.1002/hlca.19830660318

  日期：1983.5.5

  A general method for enlargement of carbocyclic rings by the so called zip reaction is given. The Michael adducts of 2-nitrocycloalkanones with 3-oxo-4-pentenoates in the presence of tetrabutylammonium fluoride give in high yield compounds with the ring enlarged by four C-atoms. By this method 7-, 8-, and 12-membered cycloalkanones were converted respectively to 11-, 12-, and 16-membered functionalized

  给出了通过所谓的拉链反应扩大碳环的一般方法。在氟化四丁基铵存在下，2-硝基环链烷酮与3-氧代-4-戊烯酸酯的迈克尔加成反应可制得高收率的化合物，其环被四个C原子扩大。通过该方法，将7元，8元和12元环烷酮分别转化为11元，12元和16元官能化的碳环（参见方案2和3）。
• Synthesis of hexahydroindol-6-ones by reaction of 2-methylthiopyrrolinium salts with Nazarov reagents
  作者：Joseph P. Michael、Mzwandile I. Zwane

  DOI：10.1016/s0040-4039(00)61277-7

  日期：1992.8

  The title compounds 6 – 8 were prepared by variations of a route commencing with base-promoted condensation of N-substituted 2-methylthio-Δ1-pyrrolinium iodides 2 with Nazarov and related reagents, followed by further manipulation of substituted enamines 11 – 14.

  该标题化合物6 - 8通过用N-取代的2-甲硫基Δ的碱促进的缩合开始的路线的变化制备1个-pyrrolinium碘化物2与纳扎罗夫和相关试剂，随后取代的烯胺的进一步操作11 - 14。
• Biochemical preparations of both the enantiomers of methyl 3-hydroxypentanoate and their conversion to the enantiomers of 4-hexanolide, the pheromone of trogoderma glabrum
  作者：Kenji Mori、Hideto Mori、Takeshi Sugai

  DOI：10.1016/s0040-4020(01)96410-5

  日期：——
• GLAZER, E. A.;PRESSLITZ, J. E., J. MED. CHEM., 1982, 25, N 7, 868-870
  作者：GLAZER, E. A.、PRESSLITZ, J. E.

  DOI：——

  日期：——